NCT07283848 2025-12-26
Zimberelimab + Domvanalimab in Gastroesophageal Adenocarcinoma
Massachusetts General Hospital
Phase 2 Withdrawn
Massachusetts General Hospital
Artiva Biotherapeutics, Inc.
Orion Biotechnology Polska Sp. z o.o.
University Hospital Tuebingen